Safety and Performance Evaluation of the Calcivis System
Launched by CALCIVIS LTD · May 23, 2016
Trial Information
Current as of June 19, 2025
Completed
Keywords
ClinConnect Summary
Dental caries (tooth decay) is a significant clinical and public health problem. The development of caries lesions involves a net mineral loss of dental tissue, which can lead to progressive loss of tooth structure and associated pain and disease. Detecting, assessing, diagnosis and treating such lesions are core activities in dentistry. Currently the main detection and diagnosis aids are visual inspection and the used of a probe, together with X-ray images. Determination of the activity status of a lesion (how likely it is to progress) is required to assess treatment needs. Currently metho...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patient must be 6 years or older
- • 2. Patient must have one unrestored, accessible, free smooth buccal surface on a canine or incisor, away from the gingival surface identified with no visible lesions (coded ICDAS 0) and/or
- • 3. Patient must have one unrestored, accessible, erupting or erupted molar or premolar with a visible lesion identified as (coded ICDAS 2 or 3) in a plaque stagnation area
- • 4. Patient and / or parent or guardian must be willing and able to give written informed consent
- • 5. Patient and / or parent or guardian must be willing and able to adhere to study schedule
- Exclusion Criteria:
- • 1. Any patient with recent tooth bleaching (within previous two weeks of imaging with the Calcivis System)
- • 2. Any patient having on-going re-mineralization treatment including, but not limited to high concentration prescription fluoride toothpaste
- • 3. Any patient with a fixed orthodontic appliance
- • 4. Any patient currently taking part in a clinical research study, or has taken part in a clinical research study in the previous three months
- • 5. Pregnant and / or nursing mothers
About Calcivis Ltd
Calcivis Ltd. is a pioneering clinical trial sponsor focused on advancing dental and oral health through innovative technologies. The company specializes in the development of cutting-edge diagnostic tools that utilize bioluminescence to detect early signs of dental decay, enabling proactive intervention and improved patient outcomes. Committed to rigorous scientific research and collaboration with dental professionals, Calcivis Ltd. aims to transform preventive dentistry and enhance the quality of care in oral health practices worldwide. With a strong emphasis on evidence-based solutions, the company is dedicated to fostering advancements that benefit both clinicians and patients in the field of dentistry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dalkeith, Edinburgh, United Kingdom
Bathgate, , United Kingdom
Edinburgh, , United Kingdom
Edinburgh, , United Kingdom
Patients applied
Trial Officials
Neil Shanks, BDS, MJDF
Study Director
Harper, Downie and Shanks Dental Practice
Elaine Downie, BDS
Principal Investigator
Harper, Downie and Shanks Dental Practice
Fraser Morrison, BDS
Principal Investigator
Bathgate Smile Centre
Steve Martin, BDS, MJDF
Principal Investigator
Edinburgh Periodontics
Agnieszka Nohawica, BDS
Principal Investigator
Bosco Dental Studio
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials